A study presented at ENDO 2025 by Dr. Shellsea Portillo Canales (SSM Health, St. Louis University Hospital) found that widely used GLP‑1 receptor agonists—semaglutide, dulaglutide, and tirzepatide—were associated with significant improvements in testosterone among obese men, many of whom also had type 2 diabetes.
After 18 months, the share of men with normal total and free testosterone levels increased from 53% to 77%, correlating with ~10% weight loss
Barron’s

🧠How It Works: Weight Loss + Hormonal Rebalancing
The improvement in testosterone appears primarily linked to weight loss, which reduces insulin resistance and lowers aromatization (conversion of testosterone to estrogen).

GLP‑1 drugs may also support the hypothalamic–pituitary–gonadal axis, increasing release of LH, FSH, and SHBG—key hormones that regulate testicular function
Reddit

An Italian pilot study reported a rapid and robust rise in testosterone (and enhancements in LH, FSH, SHBG, and erectile function) with tirzepatide over just 2 months—suggesting a direct or metabolic effect beyond weight reduction alone
MedCentral

📈 Evidence from Reviews & Animal Studies
A meta-analysis of seven clinical studies (680 participants) confirmed a significant mean rise in total testosterone (~1.4 ng/mL) after GLP‑1 therapy, alongside improvements in free testosterone and gonadotropins—and concurrent reductions in BMI and HbA1c
PubMed

A broader systematic review of semen parameters found improvements in sperm count, motility, and morphology with GLP‑1 RA therapy—especially in obese men; unlike testosterone replacement, GLP‑1 treatment maintained or improved sperm output
ICS
Men’s Reproductive Health

Animal studies in mice and in vitro models support these human findings: GLP‑1 agonists improved testicular inflammation, insulin sensitivity, and testosterone in obesity—but effects in non-obese subjects were minimal .

🧭 Key Considerations & Limitations
Primarily studied in obese or metabolically unhealthy men—benefits for lean or healthy individuals are less clear.

A U.S. via cohort study (51 men) saw no overall testosterone change after 6 months, except in those starting with low baseline testosterone (<320 ng/dL) or those who achieved significant HbA1c reduction
Endocrine Society
PubMed

Some trials suggest no effect in non-obese, healthy men receiving GLP‑1 infusions—the direct hormonal impact remains uncertain in that group
Reddit

Lean mass loss is common with GLP‑1 use, highlighting the importance of exercise and protein intake to preserve muscle—testosterone gains may help mitigate this decline to some extent .

Scant long-term data on fertility impacts or durability beyond 18 months; more controlled trials are needed.

✅ Summary Table
Finding Explanation
Testosterone normalization (53% → 77%) Observed in obese men after GLP‑1 therapy (18 months)
Rapid gains with tirzepatide Positive effects seen within 2 months in metabolic hypogonadism
Hormonal profile improvements Rise in LH, FSH, SHBG; enhanced sperm parameters
Effects tied to weight loss & metabolic health Primary driver through reduced insulin resistance & fat mass
Direct testicular effects still under study Potential GLP‑1 receptor activity in Leydig cells, plus anti-inflammatory effects
Less clear in lean or non-obese men Mixed or minimal effects observed in such populations

🩺 Implications for Men’s Health
For men with obesity or type 2 diabetes and low testosterone, GLP‑1 agonists may offer a dual benefit: weight reduction plus hormonal restoration.

These medications could provide an alternative to testosterone replacement therapy, especially where preserving fertility is a concern.

However, they are not a substitute for healthy diet, exercise, or lifestyle changes—and are not appropriate purely for raising testosterone in men with healthy weight or normal metabolic profiles.

Male patients considering GLP‑1 drugs should discuss risks and benefits with their physicians, including effects on testosterone, muscle mass, mood, and sexual function.

🧬 The Bottom Line
Emerging research indicates that GLP‑1 obesity therapies may help normalize testosterone in many obese men, correlating with better metabolic outcomes and potential improvements in reproductive health. While the promise is real, these findings are mostly early-stage—additional long-term studies are needed to confirm hormonal and fertility effects across diverse populations.